The FTSE 100 ends lower, held back by renewed risk sentiment linked to U.S.-Iran fears and by company-specific news around AstraZeneca. Investing.com reports that equities ease as concerns about tensions between the United States and Iran weigh on markets. The Independent and Belfast Telegraph both focus on AstraZeneca, saying its share performance is under pressure following a trial setback. According to The Independent, the index closes down 16.59 points, finishing at 10,472.45. While the sources agree on the overall direction of the market and the importance of AstraZeneca’s trial update, they differ in emphasis: Investing.com highlights broader geopolitical concerns, while the other outlets stress the AstraZeneca-related drag on the FTSE 100. Overall, the reports depict a session where investor caution and specific negative news in a major constituent combine to push the index lower at the close.